Immunoexpression of Matrix Metalloproteinase-2 (MMP-2) in Malignant Ovarian Epithelial Tumours

Journal of Obstetrics and Gynaecology Canada

Volumn 32, Issue 6, 2010, Pages 580-586

  Kamel, Hossam ^a   Abdelazim, Ibrahim ^a   Habib, Sherif M ^a   El Shourbagy, Mahmoud A A ^a   Ahmed, Naglaa Samier ^a  

^a AIN SHAMS UNIVERSITY   (Egypt)

Author keywords

Immunoexpression; Malignant ovarian tumours; MMP 2

Indexed keywords

GELATINASE A; MONOCLONAL ANTIBODY; PEROXIDASE;

AGE; ARTICLE; ASCITES; CANCER GRADING; CANCER GROWTH; CANCER STAGING; CANCER SURGERY; CLINICAL ARTICLE; CONTROLLED STUDY; DISTANT METASTASIS; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; METASTASIS; OMENTAL METASTASIS; OVARY CARCINOMA; PROTEIN EXPRESSION; STAINING; TUMOR INVASION; UTERINE METASTASIS; ENZYMOLOGY; METABOLISM; MIDDLE AGED; NEOPLASM; OVARY TUMOR; PATHOLOGY;

FEMALE; HUMANS; MATRIX METALLOPROTEINASE 2; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS;

EID: 77957283289     PISSN: 17012163     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1701-2163(16)34527-3     Document Type: Article

References (38)

1. Ozols R.F., Rubin S.C., Thomas G.M., Robboy S. Epithelial ovarian cance. Principles and practice of gynecologic oncology 2005, 895-988. Williams & Wilkins, Philadelphia: Lippincott. 4th ed. W.J. Hoskins, C.A. Perez, R.C. Young (Eds.).
2. Brown M.R., Blanchette J.O., Kohn E.C. Angiogenesis in ovarian cancer. Baillieres Best Pract Res Clin Obstet Gynaecol 2000, 14:901-918.
3. Arnold J.M., Cummings M., Purdie D., Chenevix-Trench G. Reduced expression of intercellular adhesion molecule-1 in ovarian adenocarcinomas. Br J Cancer 2001, 85:1351-1358.
4. Chambers A.F., Matrisian L.M. Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst 1997, 89:1260-1270.
5. Aunoble B., Sanches R., Didier E., Bignon Y.J. Major oncogenes and tumor suppressor genes involved in epithelial ovarian cancer (review). Int J Oncol 2000, 16:567-576.
6. Basset P., Okada A., Chenard M.P., Kannan R., Stoll I., Anglard P., et al. Matrix Biol 1997 Mar, 15:535-541.
7. Schmalfeldt B., Prechtel C., Härting K., Späthe K., Rutke S., Konik E., et al. Increased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer. Clin Cancer Res 2001, 7:2396-2404.
8. Fata J.E., Ho At, Leco K.J., Moorehead R.A., Khokha R. Cellular turnover of ECM remodeling in female reproductive tissues: functions of metalloproteinases and their inhibitors. Cell Mol Life Sci 2000, 57:77-95.
9. Koblinski J., Abraham A., Solane B.F. Unraveling the role of proteases in cancer. Clin Chim Acta 2000, 29:113-115.
10. Velesco G., Cal S., Merlos-Suárez A., Ferrando A.A., Alvarez S., Nakano A., et al. Human MT6-matrix metalloproteinase: identification, progelatinase A activation, and expression in brain tumors. Cancer Res 2000, 60:877-882.
11. McCawley L.J., Matrisian L.M. Matrix metalloproteinases: multifunctional contributors to tumor progression. Mol Med Today 2000, 6:149-156.
12. Aznavoorian S., Murphy A.N., Stetler-Stevenson W.G., Liotta L.A. Molecular aspect of tumor cell invasion and metastasis. Cancer 1993, 71:1368-1383.
13. Nelson A.R., Fingleton B., Rothenberg M.L., Matrisian L.M. Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol 2000, 180:1135-1149.
14. Kumaki E., Matsui K., Kawai Y., Ozeki Y., Yu Z.X., Ferrans V., et al. Expression of MMPs in invasive pulmonary adenocarcinoma with bronchioalveolar component and atypical adenomatous hyperplasia. Am J Pathol 2001, 159:2125-2135.
15. Brummer O., Böhmer G., Hollwitz B., Flemming P., Petry K.U., Kühnle H. MMP-1 and MMP-2 in cervix uteri in different steps of malignant transformation-an immunohistochemical study. Gynecol Oncol 2002, 84:222-227.
16. Chan C.C., Menges M., Orzechowski H.D., Orendain N., Pistorius G., Feifel G., et al. Increased matrix metalloproteinase 2 concentration and transcript expression in advanced colorectal carcinoma. Int J Colorectal Dis 2001, 16:133-140.
17. Vergani V., Garofalo A., Bani M.R., Borsotti P., Parker M.P., Drudis T., et al. Inhibition of MMPS by overexpression of tissue inhibitor of metalloproteinase-2 inhibits the growth of experimental hemangiomas. Int J Cancer 2001, 91:241-247.
18. Mitra A., Chakrabarti L., Chattopadhyay N., Chatterjee A. Membrane-associated MMP-2 in human cervical cancer. J Environ Pathol Toxicol Oncol 2003, 22:93.
19. Salmela M.T., Karjalainen-Lindsberg M.L., Puolakkainen P., Saarialho-Kere U. Upregulation and differential expression of matrilysin (MMP-7) and metalloelastase (MMP-12) and their inhibitors TIMP-1 and TIMP-3 in Barrett's oesophageal adenocarcinoma. Br J Cancer 2001, 85:383-392.
20. Skiles J.W., Gonnella N.C., Jeng A.Y. The design, structure, and therapeutic application of matrix metalloproteinase inhibitors. Curr Med Chem 2001, 8:425-474.
21. Zhou C.Y., Yao J.F., Chen X.D. Expression of matrix metalloproteinase-2, 9 and their inhibitor-TIMP 1,2 in human squamous cell carcinoma of uterine cervix. [article in Chinese]. Ai Zheng 2002, 21:735-739.
22. Asha Nair S., Karunagaran D., Nair M.B., Sudhakaran P.R. Changes in matrix metalloproteinases and their endogenous inhibitors during tumor progression in the uterine cervix. J Cancer Res Clin Oncol 2003, 129:123-131.
23. Rubin S.C., Sabbatini P., Randal M.E. Ovarian cancer. Cancer management: a multidisciplinary approach 2000, 409-428. PRR Inc, Mellville, NY. 4th ed. R. Pazdur, W.H. Hoskins, L. Wagman (Eds.).
24. Hsu S.M., Raine L., Fanger H. A comparative study of the peroxidase-antiperoxidase method and an avidin-biotin complex method for studying polypeptide hormones with radioimmunoassay antibodies. Am J Clin Pathol 1981, 75:734-738.
25. Davidson B., Goldberg I., Gotlieb W.H., Kopolovic J., Ben-Baruch G., Nesland J.M., et al. The prognostic value of metalloproteinases and angiogenic factors in ovarian carcinoma. Mol Cell Endocrinol 2002, 187:39-45.
26. Isnard N., Legeais J.M., Renard G., Robert L. Effect of hyaluronan on MMP expression and activation. Cell Biol Int 2001, 25:735-739.
27. Bischof P., Compana A. Molecular mediators of implantation. Baillieres Best Pract Res Clin Obstet Gynaecol 2000, 14:801-814.
28. Balbin M., Fueyo A., Knäuper V., López J.M., Alvarez J., Sánchez L.M., et al. Identification and enzymatic characterization of two diverging murine counterparts of human interstitial collagenase (MMP-1) expressed at sites of embryo implantation. J Biol Chem 2001, 276:10253-10262.
29. Nasr M., Ayyad S.B., El-Lamie I.K., Mikhail M.Y. Expression of matrix metalloproteinases in preinvasive and invasive carcinoma of the uterine cervix. Eur J Gynaecol Oncol 2005, 26:199-202.
30. Wu X., Li H., Kang L., Li L., Wang W., Shan B. Activated matrix metalloproteinase-2-a potential marker of prognosis for epithelial ovarian cancer. Gynecol Oncol 2002, 84:126-134.
31. Sakata K., Shigemasa K., Uebaba Y., Nagai N., Ohama K. Expression of MMP-2 and MMP-9 by cells isolated from the peritoneal fluid of women with ovarian carcinoma. Acta Cytol 2002, 46:697-703.
32. Cai W., Song J.D. Expression of matrix metalloproteinase in ovarian tumors [article in Chinese]. Ai Zheng 2002, 21:91-94.
33. Sakata K., Shigemasa K., Nagai N., Ohama K. Expression of matrix metalloproteinases (MMP-2, MMP-9, MT1-MMP) and their inhibitors (TIMP-1, TIMP-2) in common epithelial tumors of the ovary. Int J Oncol 2000, 17:673-681.
34. Yabushita H., Shimazu M., Noguchi M., Kishida T., Narumiya H., Sawaguchi K., et al. Vascular endothelial growth factor activating matrix metalloproteinase in ascetic fluid during peritoneal dissemination of ovarian cancer. Oncol Rep 2003, 10:89-95.
35. Afzal S., Lalani E.N., Foulkes W.D., Boyce B., Tickle S., Cardillo M.R., et al. Matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression and synthetic matrix metalloproteinase-2 inhibitor binding in ovarian carcinomas and tumor cell lines. Lab Invest 1996, 74:406-421.
36. Moser T.L., Pizzo S., Bafetti L.M., Fishman D.A., Stack M.S. Evidence for preferential adhesion of ovarian epithelial carcinoma cells to type 1 collagen mediated by the alpha2beta1 integrin. Int J Cancer 1996, 67:695-701.
37. Rowinsky E., Hammond L., Aylesworth C., Humphrey R., Siu L., Smith L., et al. Prolonged administration of Bay 12-9566, an oral nonpeptidic biphenyl matrix metalloproteinase inhibitor: a phase 1 and PK study. Proceedings of the American Society of Clinical Oncology 1998, 17:216a.
38. Goel R., Chouinard E., Stewart D., Huan S., Hirte H., Stafford S., et al. Phase I/pharmacokinetic study of the metalloproteinase inhibitor Bayer 12-9566 (BAY) in conjunction with 5-fluorouracil/folinic acid (FU/FA). The Proceedings of the American Society of Clinical Oncology 2000, 19:232a.